Jun. 3 at 9:02 PM
$SPRO FDA decision date is too well known/anticipated. SPRO remains royalty stub equity with no control over its future destiny, too high cost structure to cash royalty checks and an unproven management team/Board in terms of capital allocation.
The only catalysts that work for SPRO which isn't priced in or unexpected by the market.
Tebi asset sale + reverse merge ...
Otherwise everyone will be sorely disappointed with a no growth business with no prospects except for a quarterly royalty check to pay
$7.5 million corporate overhead to do nothing but collect checks and spend it on non value creating overhead.
I was told PDUFA decisions were super important and then I saw
$ARVN $MNKD etc
